Budesonide should be used with caution in patients with thyroid disease, cardiovascular disease, diabetics, glaucoma, cataracts and myasthenia gravis.
Budesonide should be used with caution in patients with hepatic impairment because hepatic impairment may affect elimination of budesonide.
Budesonide should be used with caution in patients at risk for osteoporosis, seizures and GI diseases (diverticulitis, peptic ulcer, ulcerative colitis).
Budesonide should be used with caution in patients with acute myocardial infarction because corticosteroids have been associated with myocardial rupture.
Bronchospasm may occur following oral inhalation of budesonide. If bronchospasm occurs, stop budesonide and treat immediately with a short-acting inhaled bronchodilator.
Particular care is needed in patients who are switched from oral systemic corticosteroid to orally inhaled corticosteroid because the symptoms of steroid withdrawal caused by adrenal insufficiency may occur. Moreover, patients may experience the return of previous symptoms such as muscle and joint pain, allergies which were previously controlled by systemic steroid.
The growth of children and adolescents who are on long term treatment with corticosteroids should be monitored. The benefits of the corticosteroid therapy must be weighed against the possible risks of growth suppression.
Effects on ability to drive and use machine: PULVISONIDE 200 has no or negligible influence on the ability to drive and use machines.